Shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Rating) have been assigned an average recommendation of “Hold” from the seven ratings firms that are presently covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $14.00.
Several brokerages recently commented on RLMD. SVB Leerink lowered their price target on Relmada Therapeutics from $42.00 to $10.00 and set an “outperform” rating for the company in a research note on Monday, January 23rd. Truist Financial decreased their target price on Relmada Therapeutics from $7.00 to $4.00 in a research report on Thursday, December 8th.
Relmada Therapeutics Price Performance
Shares of RLMD opened at $2.47 on Tuesday. The company has a market capitalization of $74.35 million, a price-to-earnings ratio of -0.42 and a beta of 0.15. Relmada Therapeutics has a fifty-two week low of $1.81 and a fifty-two week high of $38.68. The business’s 50-day moving average is $3.69 and its 200-day moving average is $10.51.
Institutional Inflows and Outflows
Relmada Therapeutics Company Profile
Relmada Therapeutics, Inc is a clinical-stage biotechnology company, which focuses on addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications.
- Get a free copy of the StockNews.com research report on Relmada Therapeutics (RLMD)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Relmada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relmada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.